MARKET

OBIO

OBIO

Orchestra BioMed Holdings Inc
NASDAQ
4.435
-0.025
-0.56%
Opening 14:55 08/11 EDT
OPEN
4.270
PREV CLOSE
4.460
HIGH
4.650
LOW
4.270
VOLUME
253.31K
TURNOVER
--
52 WEEK HIGH
5.42
52 WEEK LOW
2.200
MARKET CAP
265.57M
P/E (TTM)
-3.9040
1D
5D
1M
3M
1Y
5Y
1D
Orchestra BioMed Holdings Price Target Raised to $10.00/Share From $9.00 by Piper Sandler
Dow Jones · 6h ago
Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10
Benzinga · 7h ago
Orchestra BioMed Holdings (OBIO) Receives a Buy from Piper Sandler
TipRanks · 9h ago
Orchestra Q2 Loss Widens On Higher Expenditure; Gains $35 Mln In Strategic Capital
NASDAQ · 10h ago
Orchestra BioMed reports Q2 EPS (37c), consensus (38c)
TipRanks · 22h ago
Orchestra BioMed GAAP EPS of -$0.38
Seeking Alpha · 23h ago
Orchestra BioMed Holdings, Inc. Q2 Sales Decline
NASDAQ · 23h ago
Weekly Report: what happened at OBIO last week (0803-0807)?
Weekly Report · 1d ago
More
About OBIO
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. The Company’s lead product candidates include Atrioventricular Interval Modulation (AVIM) therapy for the treatment of hypertension (HTN), the leading risk factor for death worldwide and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. The Company develops bioelectronic therapies based on patented Cardiac Neuromodulation Therapy (CNT) technology. The AVIM is a bioelectronic therapy candidate designed to substantially and persistently lower blood pressure. Its Virtue SAB is a proprietary drug/device combination product candidate for the treatment of artery disease that is designed to deliver a proprietary, investigational, extended-release formulation of sirolimus (SirolimusEFR) to the vessel wall during balloon angioplasty without the need for balloon coating or a permanent implant.

Webull offers Orchestra Biomed Holdings Inc stock information, including NASDAQ: OBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OBIO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OBIO stock methods without spending real money on the virtual paper trading platform.